When a patient’s therapeutic objectives are not met, therapeutic inertia is the failure to initiate, intensify, or sometimes de-intensify therapy. It is a frequent issue

In November 2022, the U.S. Food and Drug Administration approved teplizumab, a CD3- directed monoclonal antibody and the first drug to be approved for the

In a new feature at the 83 Scientific Sessions, six diabetes innovators will have the opportunity to present their ideas to a panel of potential

Genome-wide association studies (GWAS) and polygenic risk scores (PRS) are two significant concepts in the field of genetics that have demonstrated promise as new tools

“First-of-its-Kind Data Underscore Importance of Early Use of Drug Therapy as a Primary Prevention,Especially for Those Living with Diabetes” Today, a new study revealed information

As part of the session “Efficacy. Engagement, and Sustainability of Dietary Management Options in Type 2 Diabetes – Time for a Reappraisal?” This Paper Was

As part of the session “Efficacy. Engagement, and Sustainability of Dietary Management Options in Type 2 Diabetes – Time for a Reappraisal?” This Paper Was

As part of the session “Real-World Hypoglycaemia in Older Adults with Diabetes” This Paper Was Presented By Drs Emily Tang, Ilana Peterson, Christine Board, Richard

As part of the session “Real-World Hypoglycaemia in Older Adults with Diabetes” This Paper Was Presented By Drs Gemma A. Lewis, Janet Cardwell, Sumudu Bujawansa,

Cardiovascular concerns are on the rise for people with diabetes, both in terms of acute and chronic complications, and a panel of scientists will discuss